CD4 and infection: Next, we evaluated the latency reversal potential of the inhibitors in a more clinically relevant primary ex vivo infection latency model, in which CD4+ T cells are infected with a full-length non-replication-competent HIV-1 virus driving expression of a luciferase reporter (Fig. 4C) (77).